The US Food and Drug Administration (FDA) has approved Tysabri (Natalizumab), a monoclonal antibody for the treatment of moderate to severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies. So reports MediceNews.net.
Crohn’s disease is an inflammatory bowel disorder that can affect the whole of the gastrointestinal tract from mouth to anus. It leads to a wide variety of symptoms, primarily abdominal pain, diarrhea, vomiting, or weight loss. It can also cause serious complications outside the gastrointestinal tract such as skin rashes, arthritis and eye inflammation.
Crohn’s disease patients using the newly approved drug must be enrolled in a special restricted distribution program called the Crohn’s Disease—Tysabri Outreach Unified Commitment to Health (CD TOUCH) Prescribing Program.